Trial Profile
A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; BMS 813160; Ipilimumab; Linrodostat
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms FRACTION-RCC
- Sponsors Bristol-Myers Squibb
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 22 Feb 2022 Planned End Date changed from 18 Jan 2023 to 27 Jan 2024.
- 22 Feb 2022 Status changed from recruiting to active, no longer recruiting.